Integration of Network Pharmacology and Experimental Validation to Explore Jixueteng - Yinyanghuo Herb Pair Alleviate Cisplatin-Induced Myelosuppression

Overview

Journal Integr Cancer Ther

Publisher Sage Publications

Specialties Oncology
Pharmacology

Date 2024 Mar 11

PMID 38462913

Authors

Yi Liu

Shuying Dai

Yixiao Xu

Yuying Xiang

Yao Zhang

Zeting Xu

Lin Sun

Gao-Chen-Xi Zhang

Qijin Shu

Affiliations

Soon will be listed here.

Abstract

Jixueteng, the vine of the bush Dunn., is widely used to treat irregular menstruation and arthralgia. Yinyanghuo, the aboveground part of the plant Maxim., has the function of warming the kidney to invigorate yang. This research aimed to investigate the effects and mechanisms of the Jixueteng and Yinyanghuo herbal pair (JYHP) on cisplatin-induced myelosuppression in a mice model. Firstly, ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) screened 15 effective compounds of JYHP decoction. Network pharmacology enriched 10 genes which may play a role by inhibiting the apoptosis of bone marrow (BM) cells. Then, a myelosuppression C57BL/6 mice model was induced by intraperitoneal (i.p.) injection of cis-Diaminodichloroplatinum (cisplatin, CDDP) and followed by the intragastric (i.g.) administration of JYHP decoction. The efficacy was evaluated by blood cell count, reticulocyte count, and histopathological analysis of bone marrow and spleen. Through the experiments, we found the timing of JYHP administration affected the effect of drug administration, JYHP had a better therapeutical effect rather than a preventive effect. JYHP obviously recovered the hematopoietic function of bone marrow from the peripheral blood cell test and pathological staining. Flow cytometry data showed JYHP decreased the apoptosis rate of BM cells and the western blotting showed JYHP downregulated the cleaved Caspase-3/Caspase-3 ratios through RAS/MEK/ERK pathway. In conclusion, JYHP alleviated CDDP-induced myelosuppression by inhibiting the apoptosis of BM cells through RAS/MEK/ERK pathway and the optimal timing of JYHP administration was after CDDP administration.

References

Deng S, Zeng Y, Xiang J, Lin S, Shen J . Icariin protects bone marrow mesenchymal stem cells in aplastic anemia by targeting MAPK pathway. Mol Biol Rep. 2022; 49(9):8317-8324. DOI: 10.1007/s11033-022-07645-1. View

Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, DallOrso S . Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol. 1999; 27(9):1460-6. DOI: 10.1016/s0301-472x(99)00076-4. View

Kemp K, Morse R, Wexler S, Cox C, Mallam E, Hows J . Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy. Ann Hematol. 2010; 89(7):701-13. DOI: 10.1007/s00277-009-0896-2. View

Wang X, Martindale J, Holbrook N . Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000; 275(50):39435-43. DOI: 10.1074/jbc.M004583200. View

Sampi K, Sakurai M, Kumai R, Maseki N, Kaneko Y, Hattori M . Combination of pipemidic acid, colistin sodium methanesulfonate and nystatin may be less effective than nystatin alone for prevention of infection during chemotherapy-induced granulocytopenia in acute leukemia. Med Oncol Tumor Pharmacother. 1989; 6(4):291-6. DOI: 10.1007/BF02985164. View

Yeager A, LEVIN F, Levin J . Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels. J Cell Physiol. 1982; 112(2):222-8. DOI: 10.1002/jcp.1041120210. View

Short C, Lim H, Tan J, ONeill H . Targeting the Spleen as an Alternative Site for Hematopoiesis. Bioessays. 2019; 41(5):e1800234. DOI: 10.1002/bies.201800234. View

Salehcheh M, Safari O, Khodayar M, Mojiri-Forushani H, Cheki M . The protective effect of herniarin on genotoxicity and apoptosis induced by cisplatin in bone marrow cells of rats. Drug Chem Toxicol. 2020; 45(4):1470-1475. DOI: 10.1080/01480545.2020.1842883. View

Takano F, Tanaka T, Aoi J, Yahagi N, Fushiya S . Protective effect of (+)-catechin against 5-fluorouracil-induced myelosuppression in mice. Toxicology. 2004; 201(1-3):133-42. DOI: 10.1016/j.tox.2004.04.009. View

10.

Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Perez J . Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007; 7(1):3-18. DOI: 10.2174/187152007779314044. View

11.

Fuertes M, Castilla J, Alonso C, Perez J . Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003; 10(3):257-66. DOI: 10.2174/0929867033368484. View

12.

Cuomo M, Platt G, Pearl L, Mittnacht S . Cyclin-cyclin-dependent kinase regulatory response is linked to substrate recognition. J Biol Chem. 2011; 286(11):9713-25. PMC: 3059039. DOI: 10.1074/jbc.M110.173872. View

13.

Barabas K, Milner R, Lurie D, Adin C . Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2009; 6(1):1-18. DOI: 10.1111/j.1476-5829.2007.00142.x. View

14.

Dasari S, Njiki S, Mbemi A, Yedjou C, Tchounwou P . Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy. Int J Mol Sci. 2022; 23(3). PMC: 8835907. DOI: 10.3390/ijms23031532. View

15.

Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel M . Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem. 2008; 15(26):2656-63. DOI: 10.2174/092986708786242903. View

16.

Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld J . Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995; 31(5):1319-39. DOI: 10.1016/0360-3016(94)00430-S. View

17.

Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F . Advances in Toxicological Research of the Anticancer Drug Cisplatin. Chem Res Toxicol. 2019; 32(8):1469-1486. DOI: 10.1021/acs.chemrestox.9b00204. View

18.

Osanto S, Thijssen J, Woldering V, Van Rijn J, Natarajan A, TATES A . Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinoma. Environ Mol Mutagen. 1991; 17(2):71-8. DOI: 10.1002/em.2850170202. View

19.

Arnberg H, Letocha H, Nou F, Westlin J, Nilsson S . GM-CSF in chemotherapy-induced febrile neutropenia--a double-blind randomized study. Anticancer Res. 1998; 18(2B):1255-60. View

20.

Kwon J, Kim J, Lee J, Shin H, Kim H, Song H . Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010; 66(5):889-97. DOI: 10.1007/s00280-009-1235-y. View